Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease (NEUPAD)

UCB

Status: Completed

Conditions: Idiopathic Parkinson's Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT01606670

SP1058

Details and patient eligibility

About

The primary objective of this study is to evaluate the perception of pain associated with Parkinson´s Disease in patients who receive Neupro® for the first time.

Enrollment: 93 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• The decision by the treating physician to treat a patient with Neupro® for the first time is made before the patient's participation in this Non-Interventional Study (NIS)
• A Patient Data Consent form is signed and dated by the patient
• Male and female patients that suffer from pain associated with idiopathic Parkinson's Disease according to the physician's assessment
• Patients have not been treated with Rotigotine in the past

Trial design

93 participants in 1 patient group

Neupro® Treatment

Description:

Routine treatment with Neupro® (2, 4, 6, 8, 10, 12, 14, 16 mg/24 h) as per approved label in the EU, which is applicable in the EU member state Germany.